Eli Lilly and Zyprexa – the cat is out of the bag

More on drug marketing and Big Pharma’s approach to patients and profits.

In 1996, Zyprexa was approved for the treatment of adults with schizophrenia, and a few years later, it was approved for short-term treatment of adults with manic episodes associated with bipolar disorder.

Yet despite these extremely limited approved uses, Zyprexa went on to become the top selling antipsychotic worldwide with an estimated 20 million people having used the drug and Lilly’s best-selling product, with $4.2 billion in sales in 2005, which translates into 30% of its total revenues.

The problem is, it’s actually not very good for patients’ health (an understatement) and Lilly is keen ($4.2billion a year keen) to stop the world from finding out the truth.

If you want to find out more about Zprexa and the way that Big Pharma operates, perhaps you might begin here.

3 Responses to “Eli Lilly and Zyprexa – the cat is out of the bag”

  1. Daniel Haszard Says:

    Eli Lilly makes billions on diabetes treatment and also gets $4.2 billion a year in sales of their biggest cash cow Zyprexa which has been scandalized as *causing* diabetes as a major side effect.
    Not fair~Daniel Haszard

  2. admin Says:

    “Not fair”

    I’d say that’s an understatement, Daniel.

    Good luck with your fight.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: